PANVIPREP has been actively featured across LinkedIn, FaceBook and other social media platforms or institutional pages.
The project is consistently highlighted in terms of its partner roles, scientific goals, and its place within the broader landscape of pandemic preparedness.
Platform |
~ Date |
Source / Profile |
Content Summary |
Engagement / Notes |
EU Newsletter |
Dec 2023 |
IMI CARE Final Newsletter (PDF) |
Officially announcement of PANVIPREP launch in January 2024 as CARE follow-up |
Distributed to the EU research audience |
|
~2024 |
Laboratoř Strukturní chemie (Czech Academy of Sciences) |
Local Czech-language post sharing PANVIPREP link for academic audience |
Engagement is not shown publicly |
|
~Feb 2025 |
PANVIPREP / Helmholtz HZI |
Member spotlight – chemical biology, PROTACs, PK/PD, role in antiviral discovery |
~16 reactions |
|
~Mar 2025 |
Science / Business |
Tagged PANVIPREP in a post about European pandemic preparedness |
|
|
~Apr 2025 |
Mentions PANVIPREP as successor project; CARE wrap-up context |
Posted by a major EU initiative |
|
|
~May 2025 |
PANVIPREP / Institute of Virology and Immunology (IVI) |
Role in in vitro testing, animal model coordination, and reporter virus use |
Modest engagement, post visible |
ORCID |
Active |
Etienne Decroly ORCID Profile |
Lists PANVIPREP under EU projects linked to virology & antiviral R&D |
Professional CV entry |
Develop-ment Aid |
Ongoing |
DevelopmentAid project page |
Describes goals: 25–50 hit molecules, 2 early lead compounds to PoC, use of AI/structural tools |
Indexed for funding/research access |
Institutional Website |
Ongoing |
Helmholtz HZI PK/PD Unit |
Notes PANVIPREP participation & team expertise in anti-infective preclinical research |
Institutional-level visibility |